TLIK Stock Overview
Engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arzneiwerk AG VIDA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.66 |
| 52 Week High | €1.45 |
| 52 Week Low | €0.62 |
| Beta | 0.70 |
| 1 Month Change | -11.49% |
| 3 Month Change | -28.02% |
| 1 Year Change | -54.83% |
| 3 Year Change | -92.34% |
| 5 Year Change | -37.02% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLIK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.3% | -3.1% | -2.6% |
| 1Y | -54.8% | 16.0% | 7.1% |
Return vs Industry: TLIK underperformed the German Healthcare industry which returned 19.1% over the past year.
Return vs Market: TLIK underperformed the German Market which returned 8% over the past year.
Price Volatility
| TLIK volatility | |
|---|---|
| TLIK Average Weekly Movement | 6.8% |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: TLIK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: TLIK's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 39 | Sascha Knoche | www.arzneiwerk.ag |
Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.
Arzneiwerk AG VIDA Fundamentals Summary
| TLIK fundamental statistics | |
|---|---|
| Market cap | €4.18m |
| Earnings (TTM) | -€2.15m |
| Revenue (TTM) | €59.68m |
0.1x
P/S Ratio-1.9x
P/E RatioIs TLIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIK income statement (TTM) | |
|---|---|
| Revenue | €59.68m |
| Cost of Revenue | €56.10m |
| Gross Profit | €3.58m |
| Other Expenses | €5.73m |
| Earnings | -€2.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 6.00% |
| Net Profit Margin | -3.60% |
| Debt/Equity Ratio | -201.1% |
How did TLIK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 09:35 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arzneiwerk AG VIDA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marcus Pratsch | Dz Bank Ag |